Anti-IL-6/IL-6R antibodies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11613582-B2
Application number	US-202016944828-A
Country	US
Kind code	B2
Filing date	Jul 31, 2020
Priority date	May 13, 2008
Publication date	Mar 28, 2023
Grant date	Mar 28, 2023

Abstract

This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

First claim

What is claimed is:

1. A method of treating an IL-6 signaling related disease, the method comprising administering to a subject an antibody that binds to the IL-6/IL-6R complex (IL-6Rc), wherein the antibody comprises a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 33, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 24, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 26, wherein the method alleviates one or more symptoms associated with an inflammation related disorder selected from fever, general malaise, fatigue, fever, pain, joint pain, tachypnea chills, cough, dyspnea, lung infection, respiratory disease, headache, diarrhea, rash, anemia, or reduced organ function.

2. The method of claim 1 , wherein the IL-6 signaling related disease is selected from sepsis, bone resorption, osteoporosis, cachexia, mesangial proliferative glomerulonephritis, AIDS-related lymphoma, systemic onset juvenile idiopathic arthritis, hypergammaglobulinemia, ulcerative colitis, systemic lupus erythematosus (SLE), multiple sclerosis, Castleman's disease, IgM gammopathy, cardiac myxoma, and autoimmune insulin-dependent diabetes mellitus.

Assignees

• Novimmune Sa
• Novimmune Sa

Inventors

• Ferlin Walter
• Kosco-Vilbois Marie
• Elson Greg
• Leger Olivier
• Guilhot Florence

Classifications

• C07K2317/32

  specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title